Cargando…

Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading

Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clones found in human cancers. We found that approxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuya, Genta, Katoh, Hiroto, Atsumi, Shinichiro, Hashimoto, Itaru, Komura, Daisuke, Hatanaka, Ryo, Senga, Shogo, Hayashi, Shuto, Akita, Shoji, Matsumura, Hirofumi, Miura, Akihiro, Mita, Hideaki, Nakakido, Makoto, Nagatoishi, Satoru, Sugiyama, Akira, Suzuki, Ryohei, Konishi, Hiroki, Yamamoto, Asami, Abe, Hiroyuki, Hiraoka, Nobuyoshi, Aoki, Kazunori, Kato, Yasumasa, Seto, Yasuyuki, Yoshimura, Chihoko, Miyadera, Kazutaka, Tsumoto, Kouhei, Ushiku, Tetsuo, Ishikawa, Shumpei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807517/
https://www.ncbi.nlm.nih.gov/pubmed/36136061
http://dx.doi.org/10.1111/cas.15596
_version_ 1784862736934502400
author Furuya, Genta
Katoh, Hiroto
Atsumi, Shinichiro
Hashimoto, Itaru
Komura, Daisuke
Hatanaka, Ryo
Senga, Shogo
Hayashi, Shuto
Akita, Shoji
Matsumura, Hirofumi
Miura, Akihiro
Mita, Hideaki
Nakakido, Makoto
Nagatoishi, Satoru
Sugiyama, Akira
Suzuki, Ryohei
Konishi, Hiroki
Yamamoto, Asami
Abe, Hiroyuki
Hiraoka, Nobuyoshi
Aoki, Kazunori
Kato, Yasumasa
Seto, Yasuyuki
Yoshimura, Chihoko
Miyadera, Kazutaka
Tsumoto, Kouhei
Ushiku, Tetsuo
Ishikawa, Shumpei
author_facet Furuya, Genta
Katoh, Hiroto
Atsumi, Shinichiro
Hashimoto, Itaru
Komura, Daisuke
Hatanaka, Ryo
Senga, Shogo
Hayashi, Shuto
Akita, Shoji
Matsumura, Hirofumi
Miura, Akihiro
Mita, Hideaki
Nakakido, Makoto
Nagatoishi, Satoru
Sugiyama, Akira
Suzuki, Ryohei
Konishi, Hiroki
Yamamoto, Asami
Abe, Hiroyuki
Hiraoka, Nobuyoshi
Aoki, Kazunori
Kato, Yasumasa
Seto, Yasuyuki
Yoshimura, Chihoko
Miyadera, Kazutaka
Tsumoto, Kouhei
Ushiku, Tetsuo
Ishikawa, Shumpei
author_sort Furuya, Genta
collection PubMed
description Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clones found in human cancers. We found that approximately half of the corresponding antigens were restricted to strongly and densely negatively charged polymers, resulting in simultaneous reactivities of the antibodies to both densely sulfated glycosaminoglycans (dsGAGs) and nucleic acids (NAs). These anti‐dsGAG/NA antibodies matured and expanded via intratumoral immunological driving force of innate immunity via NAs. These human cancer–derived antibodies exhibited acidic pH–selective affinity across both antigens and showed specific reactivity to diverse spectrums of human tumor cells. The antibody‐drug conjugate exerted therapeutic effects against multiple cancers in vivo by targeting cell surface dsGAG antigens. This study reveals that intratumoral immunological reactions propagate tumor‐oriented immunoglobulin clones and demonstrates a new therapeutic modality for the universal treatment of human malignancies.
format Online
Article
Text
id pubmed-9807517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98075172023-01-04 Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading Furuya, Genta Katoh, Hiroto Atsumi, Shinichiro Hashimoto, Itaru Komura, Daisuke Hatanaka, Ryo Senga, Shogo Hayashi, Shuto Akita, Shoji Matsumura, Hirofumi Miura, Akihiro Mita, Hideaki Nakakido, Makoto Nagatoishi, Satoru Sugiyama, Akira Suzuki, Ryohei Konishi, Hiroki Yamamoto, Asami Abe, Hiroyuki Hiraoka, Nobuyoshi Aoki, Kazunori Kato, Yasumasa Seto, Yasuyuki Yoshimura, Chihoko Miyadera, Kazutaka Tsumoto, Kouhei Ushiku, Tetsuo Ishikawa, Shumpei Cancer Sci Original Articles Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clones found in human cancers. We found that approximately half of the corresponding antigens were restricted to strongly and densely negatively charged polymers, resulting in simultaneous reactivities of the antibodies to both densely sulfated glycosaminoglycans (dsGAGs) and nucleic acids (NAs). These anti‐dsGAG/NA antibodies matured and expanded via intratumoral immunological driving force of innate immunity via NAs. These human cancer–derived antibodies exhibited acidic pH–selective affinity across both antigens and showed specific reactivity to diverse spectrums of human tumor cells. The antibody‐drug conjugate exerted therapeutic effects against multiple cancers in vivo by targeting cell surface dsGAG antigens. This study reveals that intratumoral immunological reactions propagate tumor‐oriented immunoglobulin clones and demonstrates a new therapeutic modality for the universal treatment of human malignancies. John Wiley and Sons Inc. 2022-10-17 /pmc/articles/PMC9807517/ /pubmed/36136061 http://dx.doi.org/10.1111/cas.15596 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Furuya, Genta
Katoh, Hiroto
Atsumi, Shinichiro
Hashimoto, Itaru
Komura, Daisuke
Hatanaka, Ryo
Senga, Shogo
Hayashi, Shuto
Akita, Shoji
Matsumura, Hirofumi
Miura, Akihiro
Mita, Hideaki
Nakakido, Makoto
Nagatoishi, Satoru
Sugiyama, Akira
Suzuki, Ryohei
Konishi, Hiroki
Yamamoto, Asami
Abe, Hiroyuki
Hiraoka, Nobuyoshi
Aoki, Kazunori
Kato, Yasumasa
Seto, Yasuyuki
Yoshimura, Chihoko
Miyadera, Kazutaka
Tsumoto, Kouhei
Ushiku, Tetsuo
Ishikawa, Shumpei
Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading
title Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading
title_full Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading
title_fullStr Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading
title_full_unstemmed Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading
title_short Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading
title_sort nucleic acid–triggered tumoral immunity propagates ph‐selective therapeutic antibodies through tumor‐driven epitope spreading
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807517/
https://www.ncbi.nlm.nih.gov/pubmed/36136061
http://dx.doi.org/10.1111/cas.15596
work_keys_str_mv AT furuyagenta nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT katohhiroto nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT atsumishinichiro nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT hashimotoitaru nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT komuradaisuke nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT hatanakaryo nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT sengashogo nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT hayashishuto nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT akitashoji nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT matsumurahirofumi nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT miuraakihiro nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT mitahideaki nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT nakakidomakoto nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT nagatoishisatoru nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT sugiyamaakira nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT suzukiryohei nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT konishihiroki nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT yamamotoasami nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT abehiroyuki nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT hiraokanobuyoshi nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT aokikazunori nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT katoyasumasa nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT setoyasuyuki nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT yoshimurachihoko nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT miyaderakazutaka nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT tsumotokouhei nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT ushikutetsuo nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading
AT ishikawashumpei nucleicacidtriggeredtumoralimmunitypropagatesphselectivetherapeuticantibodiesthroughtumordrivenepitopespreading